CSIMarket
 


Pacific Biosciences Of California Inc   (PACB)
Other Ticker:  
 
 

PACB's Capital Expenditures Growth by Quarter and Year

Pacific Biosciences Of California Inc 's Capital Expenditures results by quarter and year




PACB Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 2.02 16.93 2.84 0.07
III Quarter September 0.83 0.00 1.12 0.54
II Quarter June 2.27 4.02 1.57 0.32
I Quarter March 3.72 3.64 0.40 0.12
FY   8.84 24.59 5.93 1.05



PACB Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Pacific Biosciences Of California Inc reported drop in Capital Expenditures in the fourth quarter 2023 by -88.04% to $ 2.02 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Pacific Biosciences Of California Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures jump of 91.36%.

Looking into fourth quarter 2023 results within Laboratory Analytical Instruments industry 4 other companies have achieved higher Capital Expenditures growth. While Pacific Biosciences Of California Inc ' s Capital Expenditures meltdown of -88.04% ranks overall at the positon no. 1224 in the fourth quarter 2023.




PACB Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -88.04 % 496.13 % 3957.14 % -50 %
III Quarter September - - 107.41 % -34.94 %
II Quarter June -43.53 % 156.05 % 390.63 % -47.54 %
I Quarter March 2.2 % 810 % 233.33 % -90.4 %
FY   -64.03 % 314.67 % 464.76 % -62.9 %

Financial Statements
Pacific Biosciences Of California Inc 's fourth quarter 2023 Capital Expenditures $ 2.02 millions PACB's Income Statement
Pacific Biosciences Of California Inc 's fourth quarter 2022 Capital Expenditures $ 16.93 millions Quarterly PACB's Income Statement
New: More PACB's historic Capital Expenditures Growth >>


PACB Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 143.86 % - 153.57 % -87.04 %
III Quarter September -63.44 % - -28.66 % 68.75 %
II Quarter June -38.98 % 10.44 % 292.5 % 166.67 %
I Quarter March -78.03 % 28.17 % 471.43 % -14.29 %
FY (Year on Year)   -64.03 % 314.67 % 464.76 % -62.9 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #5
Healthcare Sector #148
Overall #1224

Capital Expenditures Y/Y Growth Statistics
High Average Low
592.97 % 91.36 % -82.23 %
(Mar 31 2022)   (Dec 31 2018)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #5
Healthcare Sector #148
Overall #1224
Capital Expenditures Y/Y Growth Statistics
High Average Low
592.97 % 91.36 % -82.23 %
(Mar 31 2022)   (Dec 31 2018)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Pacific Biosciences Of California Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
2060.34 % 102.83 % -100 %
(Mar 31 2019)  


PACB's IV. Quarter Q/Q Capital Expenditures Comment
Pacific Biosciences Of California Inc achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures doubling of 143.86%, to $ 2.02 millions, from $0.83 millions in the third quarter.
Pacific Biosciences Of California Inc is undergoing a remarkable growth, not only reporting higher then regular gain, and also improving rate, Arvid Larsson, Healthcare sector insider mentioned.

Within Laboratory Analytical Instruments industry Pacific Biosciences Of California Inc achieved highest sequential Capital Expenditures growth. While Pacific Biosciences Of California Inc 's Capital Expenditures growth quarter on quarter, overall rank is 126.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #1
Healthcare Sector #26
Overall #126
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #1
Healthcare Sector #26
Overall #126
Capital Expenditures Q/Q Growth Statistics
High Average Low
2060.34 % 102.83 % -100 %
(Mar 31 2019)  


PACB's IV. Quarter Q/Q Capital Expenditures Comment
Pacific Biosciences Of California Inc achieved in the IV. Quarter 2023 above company average sequential Capital Expenditures doubling of 143.86%, to $ 2.02 millions, from $0.83 millions in the third quarter.
Laboratory Analytical Instruments company is undergoing a remarkable growth, not just recording higher then average gain, but also improving speed.

Within Laboratory Analytical Instruments industry Pacific Biosciences Of California Inc achieved highest sequential Capital Expenditures growth. While Pacific Biosciences Of California Inc 's Capital Expenditures growth quarter on quarter, overall rank is 126.


Pacific Biosciences Of California Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 8.84 $ 23.75 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) -62.76 % - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1224 # 1189 # 773 # 505 # 307




Cumulative Capital Expenditures growth Comment


Pacific Biosciences Of California Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
592.97 %
91.36 %
-82.23 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 148
S&P 500 # 1224
Cumulative Capital Expenditures growth Comment


Pacific Biosciences Of California Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
592.97 %
91.36 %
-82.23 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 148
S&P 500 # 1224




Other Capital Expenditures Growth
Laboratory Analytical Instruments Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
PACB's Capital Expenditures Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for PACB's Competitors
Capital Expenditures Growth for Pacific Biosciences Of California Inc 's Suppliers
Capital Expenditures Growth for PACB's Customers

You may also want to know
PACB's Annual Growth Rates PACB's Profitability Ratios PACB's Asset Turnover Ratio PACB's Dividend Growth
PACB's Roe PACB's Valuation Ratios PACB's Financial Strength Ratios PACB's Dividend Payout Ratio
PACB's Roa PACB's Inventory Turnover Ratio PACB's Growth Rates PACB's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Sunshine Biopharma Inc -0.43%$ -0.431 millions
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com